SPRUCE BIOSCIENCES INC
SPRBNASDAQTrading Snapshot
- Day Range
- $46.99 – $48.21
- 52-Week Range
- $7.88 – $240.00
- Volume
- $5.08B
- Avg Volume
- $5.43B
- Shares Outstanding
- 2.8M
- Next Earnings
- Nov 9, 2026
Fundamentals Snapshot
- Annual Revenue
- $20M
- Last Q Revenue
- $5M
- P/E Ratio
- -1.2
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-21.12
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +42.9%
Why Investors Own SPRB
- ✓High-growth profile — revenue up +52.8% YoY with expanding US Equity exposure.
- ✓Healthy economics — 27% gross margin and 14% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
SPRUCE BIOSCIENCES INC
SPRB
StockOtter · stockotter.spaceAbout SPRUCE BIOSCIENCES INC
Spruce Biosciences, Inc., founded in 2014 and situated in Daly City, California, operates as a biopharmaceutical enterprise. Its primary objective is to advance and bring to market innovative treatments, particularly for uncommon endocrine conditions. A central component of its therapeutic pipeline is tildacerfont, a non-steroidal drug candidate. This compound is currently undergoing Phase 2b clinical assessments in adult patients with congenital adrenal hyperplasia (CAH), with the aim of optimizing disease management and lessening dependence on steroid medications by examining reductions in glucocorticoid levels and their clinical consequences. Tildacerfont is also progressing through Phase 2 trials for pediatric classic CAH, as well as investigating its efficacy in women suffering from polycystic ovary syndrome (PCOS). Additionally, Spruce Biosciences maintains a collaborative licensing agreement with Eli Lilly and Company to jointly explore, formulate, and commercialize various pharmaceutical substances.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Spruce Biosciences to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with sign
Spruce Biosciences Announces Launch of MPS3BStudy.com
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disor
Spruce Biosciences Announces Positive Pre-BLA Meetings with FDA and Confirms BLA Submission for TA-ERT on Track for Q4 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB) (“Spruce”), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorder
Cure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce Biosciences
Spruce Biosciences, Inc. (Nasdaq: SPRB) a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disord
Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with sign
Spruce Biosciences Appoints Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (“Spruce Biosciences” or “Spruce”) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies f